Client News
Mainz Biomed Announces Live Launch of ColoAlert® with Bioclinica in Romania
4th October 2023
Newron to present three posters on its clinical program evaluating evenamide in the treatment of schizophrenia at the 36th European College of Neuropsychopharmacology Congress
4th October 2023
Carbios unveils major innovation in polyester recycling with new textile preparation line, in the presence of Roland Lescure, French Minister of Industry
2nd October 2023
Abivax highlights obefazimod ulcerative colitis program with new data to be presented at the UEG Week 2023
2nd October 2023
Newron appoints Margarita Chavez as board advisor
2nd October 2023
Abivax files registration statement for proposed initial public offering in the United States
29th September 2023
Abivax announces the release of its 2023 half-year financial report
29th September 2023
Ilmac 2023 in Basel was a resounding success
29th September 2023
Affluent Medical: H1 2023 RESULTS – Major advances in clinical programs – Extension of cash horizon to February 2024
28th September 2023
AiCuris´ AiCubator Program Opens New Application Round for Innovative Projects with Focus on Treatment Options for Viral Infections in Immunocompromised Patients
28th September 2023
Carbios announces half-year 2023 financial results and corporate update
28th September 2023
Medigene AG Secures European Patent for its PD1-41BB Costimulatory Switch Protein
27th September 2023
Mainz Biomed to Present Detailed Results of ColoFuture Study at International Conference on Gastroenterology
27th September 2023
Destiny Pharma: Destiny Pharma: Notice of XF Pipeline Update Meeting
27th September 2023
Abivax presents first-half 2023 financial results
21st September 2023
Destiny Pharma: Interim results for the six months ended 30 June 2023
20th September 2023
Mainz Biomed to Present at the Cantor Fitzgerald Global Healthcare Conference
20th September 2023
Rentschler Biopharma appoints Benedikt von Braunmuehl as Chief Executive Officer
19th September 2023
Atriva Therapeutics Announces Exclusive Letter Agreement for Reverse Takeover Transaction with Biocure Technology
18th September 2023
Medigene AG Announces Lead Selection for MDG2011 Representing the First TCR-T Therapy of its KRAS Library
18th September 2023
Affluent Medical announces positive clinical results and further insights to enhance its strategy on Structural Heart activities
13th September 2023
Imcyse Announces Completion of Enrollment in Phase 1 Clinical Trial of ImotopeTM IMCY-0141 for the Treatment of Multiple Sclerosis
13th September 2023
Rentschler Biopharma’s ATMP facility in Stevenage, UK, receives MHRA approval
13th September 2023
Mainz Biomed’s ColoFuture Study, Evaluating its Novel mRNA Biomarkers, Reports Groundbreaking Topline Results Demonstrating Sensitivity for Colorectal Cancer of 94% with Specificity of 97% and Advanced Adenoma Sensitivity of 81%
13th September 2023
InflaRx Announces Positive Topline Results from the Single Ascending Dose (SAD) Phase I Study with C5aR Inhibitor INF904
11th September 2023
Adrenomed presents new findings on its precision medicine treatment for septic shock with enibarcimab during Weimar Sepsis Update
8th September 2023
Abivax provides business and operational update
7th September 2023
AdhereTech Appoints Innes Meldrum as President and Chief Executive Officer
6th September 2023
Proteros biostructures and Orion Pharma agree on a long-term multi-target collaboration including the assembly of a joint novel and unique HTS small-molecule screening library with the full chemistry support of Enamine
6th September 2023
Element Materials unveils fully integrated pharma services platform, strengthening its expanding Life Sciences Division
5th September 2023
invIOs starts further clinical trial of APN401, novel cell therapy against solid cancers, and secures major Austrian grant funding
5th September 2023
Mainz Biomed Announces Strategic Partnership with Ärztliches Labor Dr. Buhlmann, Expanding Footprint in German Market
5th September 2023
iOmx Therapeutics appoints Dr. Nils Peter Debus as Chief Business Officer
5th September 2023
InflaRx’s Marketing Authorization Application (MAA) for Vilobelimab for Treatment of Critically Ill COVID-19 Patients under Review by European Medicines Agency (EMA)
30th August 2023
Abivax Appoints Patrick Malloy as Senior Vice President Investor Relations
23rd August 2023
